Antitumor activity of a PKC-α antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice

Anti-Cancer Drug Design

Volumn 13, Issue 1, 1998, Pages 35-45

  Geiger, Thomas ^a   Müller, Marcel ^a   Dean, Nicholas M ^b   Fabbro, Doriano ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense; Antitumor activity; Combination; Cytotoxin; Oligonucleotide

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; DOXORUBICIN; ESTRAMUSTINE PHOSPHATE; ISIS 3521; MITOMYCIN C; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN KINASE C; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER GRAFT; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LARGE CELL CARCINOMA; LUNG SMALL CELL CANCER; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; ISOENZYMES; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; THIONUCLEOTIDES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

ANIMALIA; MINK CELL FOCUS-FORMING VIRUS; MUS MUSCULUS;

EID: 0031963427     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. BASU, A. (1993). A potential of protein kinase C as a target for anticancer treatment. Pharmaceutical Therapy, 59, 257.
2. BLAGOSKLONNY, M.V. & NECKERS, L.M. (1994). Oligonucleotides protect cells from the cytotoxicity of several anti-cancer chemotherapeutic drugs. Anti-Cancer Drug Design, 5, 437.
3. CHIANG, M.Y., CHAN, H., ZOUNES, M. A., FREIER, S.M., LIMA, W.F. & BENNETT C.F. (1991). Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. Journal of Biological Chemistry, 266, 18162.
4. CROOKE, S.T. (1992). Therapeutic applications of oligonucleotides. Annual Review of Pharmacology Toxicology, 32, 329.
5. CROOKE, S.T. (1995). Progress in antisense therapeutics. Hematological Pathology, 9, 59.
6. CROOKE, S.T. & BENNETT, C.F (1996). Progress in antisense oligonucleotide therapeutics. Annual Review of Pharmacology Toxicology, 36, 107.
7. DEAN, N.M., MCKAY, R., CONDON, T.P. & BENNETT, C.F. (1994). Inhibition of protein kinase C-α expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. Journal of Biological Chemistry, 269, 16416.
8. DEAN, N.M., MCKAY, R., MIRAGLIA, L., HOWARD, R., MEISTER, L., ZIEL, R., GEIGER, T, MÜLLER, M. & FABBRO, D. (1996). Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of PKC-a expression. Cancer Research, 15, 3499.
9. EVANS, B.D., MITH, I.E., SHORTHOUSE, A.J. & MILLAR, J.J. (1982). A comparison of the response of human lung cell carcinoma to vindesine and vincristine. British Journal of Cancer, 45, 466.
10. LESZCZYNSKI, D., ZHAO, Y, LUOKKAMAKI, M. & FOEGH, M.L. (1994). Apoptosis of vascular smooth muscle cells. American Journal of Pathology, 145, 1265.
11. MILLIGAN, J.F., MATTEUCCI, M.D. & MARTIN, J.C. (1993). Current concepts in antisense drug design. Journal of Medicinal Chemistry, 36, 1923.
12. NISHIZUKA, Y. (1995). Protein kinase C and lipid for sustained cellular response. FASEB Journal, 9, 484.
13. O'BRIEN, S.G., KIRKLAND, M.A., MELO, J.V., RAO, M.H., DAVIDSON, R., MCDONALD, C. & GOLDMAN, J.M. (1994). Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. Leukemia, 8, 2156.
14. PEREZ, J.R., LI, Y., STEIN, C.A., MAJUMDER, S., VAN OORSCHOT, A. & NARAYANA, R, (1994). Sequence- independent induction of Sp1 transcription factor activity by phosphorothioate oligonucleotides. Proceedings of the National Academy of Sciences, USA, 91, 5957.
15. SCHWARTZ, G.K., HAIMOVITZ-FRIEDMAN, A., DHUPAR, S.K., EHLEITER, D., MASLAK, P., LAI, L., LAGANZO, F., KELSEN, D.P., FUKS, Z. & ALBINO, A.G. (1995). Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells. Journal of the National Cancer Institute, 87, 1394.
16. STULL, R.A., ZON, G. &. SZOKA, F.C (1993). Single-stranded phosphodiester and phosphorothioate oligonucelotides bind actinomycin D and interfere with tumor necrosis factor-induced lysis in the L929 cytotoxicity assay. Antisense Research and Development, 3, 295.
17. SUN, Y., POMMIER, Y. & COLBURN, N.H. (1992). Acquisition of a growth-inhibitory response to phorbol ester involves DNA damage. Cancer Research, 52, 1907.
18. SWYATT, J.R., VICKERS, T.A., ROBERSON, J.L., BUCKHEIT, R.W., KLIMKAIT, T., DE BAETS, E., DAVIS, P.W., RAYNER, B. &. ECKER, D.J. (1994). Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proceedings of the National Academy of Sciences, USA, 91, 1356.
19. WAYS, D.K., KUKOLY, C.A., DE VENTE, I., HOOKER, J.L., BRYANT, W.O., POSEKAN, K.J., FLETCHER, D.J., COOK, P.P. & PARKER, P.P. (1995). MCF-7 breast cancer cells transfected with PKC-α exhibit altered expression of other ptoein kinase isoforms and display a more aggressive neoplastic phenotype. Journal of Clinical Investigations, 95, 1906.
20. YASWEN, P., STAMPFER, M.R., GHOSH, K. & COHEN J.S. (1993). Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Research and Development, 3,67.